Omnix Medical

Company Overview

Snapshot

Founded in May 2015 by Moshik Cohen-Kutner and Niv Bachnoff, Omnix Medical operates with 11–50 employees. The company has raised $52.9M across 6 funding rounds from 11 investors. In July 2026, Omnix Medical was selected to lead a European consortium focused on accelerating the late-stage development of its experimental treatment for drug-resistant hospital infections.

Business overview

Omnix Medical is a clinical-stage biopharmaceutical company dedicated to developing next-generation anti-infective drugs to combat resistant bacteria. The company's core technology mimics the innate immune system of insects, utilizing unique molecules to selectively eliminate resistant bacterial strains without toxic effects, thereby preventing the development of new resistances. Omnix Medical's lead compound, OMN6, is a novel, first-in-class antimicrobial peptide (AMP) being developed for life-threatening hospital-acquired infections caused by Acinetobacter baumannii, serving the pharmaceuticals and life sciences markets.

Strategic signal

In June 2026, Omnix Medical announced the first patients were dosed in its. This milestone signals significant progress in the clinical development of a novel therapy for hospital-acquired infections, validating the company's approach to addressing drug-resistant bacteria and moving closer to potential market entry.

Company Intelligence Q&A

When did Omnix Medical begin its Phase II trial for OMN6?

In June 2026, Omnix Medical announced that the first patients were dosed in its.

Which investors participated in Omnix Medical's October 2025 funding round?

In October 2025, Omnix Medical secured funding from investors including.

Who are the co-founders of Omnix Medical?

Omnix Medical was co-founded by Moshik Cohen-Kutner, who serves as CEO, and Niv Bachnoff, who is the CSO.